CVS Health Corp (CVS) : Dixon Hubard Feinour Brown Incva reduced its stake in CVS Health Corp by 2.03% during the most recent quarter end. The investment management company now holds a total of 73,425 shares of CVS Health Corp which is valued at $7,153,798 after selling 1,522 shares in CVS Health Corp , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.CVS Health Corp makes up approximately 2.21% of Dixon Hubard Feinour Brown Incva’s portfolio.
Other Hedge Funds, Including , Washington Trust Co reduced its stake in CVS by selling 10,296 shares or 2.81% in the most recent quarter. The Hedge Fund company now holds 356,105 shares of CVS which is valued at $34,695,310. CVS Health Corp makes up approx 2.23% of Washington Trust Co’s portfolio.Bank Of The West boosted its stake in CVS in the latest quarter, The investment management firm added 9,338 additional shares and now holds a total of 61,912 shares of CVS Health Corp which is valued at $6,028,371. CVS Health Corp makes up approx 0.82% of Bank Of The West’s portfolio.Concert Wealth Management boosted its stake in CVS in the latest quarter, The investment management firm added 4,021 additional shares and now holds a total of 12,994 shares of CVS Health Corp which is valued at $1,204,804. CVS Health Corp makes up approx 0.16% of Concert Wealth Management’s portfolio.Cwm reduced its stake in CVS by selling 294 shares or 98.0% in the most recent quarter. The Hedge Fund company now holds 6 shares of CVS which is valued at $579.
CVS Health Corp closed down -0.73 points or -0.74% at $97.27 with 30,04,431 shares getting traded on Tuesday. Post opening the session at $98.27, the shares hit an intraday low of $97.1 and an intraday high of $98.44 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, CVS Health Corp reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $1.30. The company had revenue of $43725.00 million for the quarter, compared to analysts expectations of $44281.46 million. The company’s revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 EPS.
Many Wall Street Analysts have commented on CVS Health Corp. Company shares were Reiterated by Mizuho on Aug 4, 2016 to “Buy”, Firm has raised the Price Target to $ 111 from a previous price target of $108 .Company shares were Reiterated by Deutsche Bank on Aug 3, 2016 to “Hold”, Firm has raised the Price Target to $ 108 from a previous price target of $99 .Shares were Reiterated by Mizuho on Jun 23, 2016 to “Buy” and Lowered the Price Target to $ 108 from a previous price target of $117 .
CVS Health Corporation together with its subsidiaries is a pharmacy company. The Company operates through three business segments: Pharmacy Services Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services Novologix and Navarro Health Services names. The Retail Pharmacy segment sells prescription drugs and an assortment of general merchandise including over-the-counter drugs beauty products and cosmetics personal care products convenience foods photo finishing seasonal merchandise and greeting cards through the Company’s retail stores online retail pharmacy Websites and retail healthcare clinics. The Corporate segment provides management and administrative services to support the overall operations of the Company. The Company through its wholly owned subsidiary Omnicare Inc. provides pharmacy services to long term care facilities.